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The next generation of devices for personal healthcare monitoring will comprise molecular sensors to monitor
analytes of interest in the skin compartment. Transdermal devices based on microneedles offer an excellent op-
portunity to explore the dynamics of molecular markers in the interstitial uid, however good acceptability ofﬂ
these next generation devices wi ll requi re sev eral technical problems associat ed wi th curren t com mercially
available wearable sensors to be overcome. These particularly include reliability, comfort and cost. An essential
pre-requisite for transdermal molecular sensing devices is that they can be fabricated using scalable technologies
which are cost effective.
We present here a minimally invasive microneedle array as a continuous monitoring platform technology. Meth-
od for scalable fabrication of these structures is presented. The microneedle arrays were characterised mechan-
ically and were shown to penetrate human skin under moderate thumb pressure. They were then functionalised
and evaluated as glucose, lactate and theophylline biosensors. The results suggest that this technology can be
employed in the measurement of metabolites, therapeutic drugs and biomarkers and could have an important
role to play in the management of chronic diseases.





Continuous glucose monitoring (CGM)
Continuous lactate monitoring (CLM)
Interstitial therapeutic drug monitoring (iTDM)
1. Introduction
The current gene ration of wearable devices for personal wellness
monito ring such as the Fitbit (Fitb it), U P3 (Ja wbone) and SIM band
(Samsung) comprises a variety of physical sensors that measure param-
eters such as movement, heart rate, electrocardiogram (ECG), galvanic
skin response, bioimpedance, and skin temperature. The next genera-
tion of wearable smart devices will also incorporate non-invasive/min-
imally invasive molecular sensors. The main challenges anticipated for
these sm art devic es would be s imilar to th e ones faced currently by
the physical sensors particularly in terms of reliability, cost and the eth-
ical issues associated with ownership and use of continuous bio-signal
obtained in real time.
Transdermal devices consisting of microstructures such as hollow
[25], swellable , coated[1,27] [8,13,26], and solid microneedles [2,6,14,
24] [25], have been used mainly for vaccine , and drug delivery [12,22]
but there is a rapidly growing interest in using them for molecular sens-
ing [4,7,15,17,19,23]. The interstitial ﬂuid (ISF) in the skin compartment
exhibits a dynamic exchange of small to medium sized molecules with
capillary blood thereby offering access to a nalytes with minima l trauma
and in a c ontinuo us manner , somet h ing that could be pote ntiall y of
great cl inical uti lity. The main applicat ion where minimally invasive,
continuous measurement is of immense value is in continuous glucose
monitoring for diabetes. However with suitable devices this could also
be extended to lactate monitoring in athletes for performance training,
interstitial therapeutic drug monitoring as well as lifestyle related appli-
cations such as help in smoking cessation.
Interstitial uid has been extensively explored for metabolites suchﬂ
as glucose and lac ta te . Co ntinuous gluc ose monitor ing (CGM)[3,18]
has been most intensively studied and there is good clinical evidence
that effective CGM in Type 1 diabetes leads both to a reduced frequency
of hypoglycaemic episodes and lowered HbA1c [21].
Minimally invasive, continuous monitoring of lactate in the intersti-
tial ﬂuid could also offer a more informative measure of this metabolite
that would allow athletes to monitor it during their training rather than
taking a single (venous blood) measurement at the end .[9]
The IS F microenvi ronment also offers a compartment in which to
measu re the dynamics of ther apeutic d rugs and bioma rkers duri ng
treatment. There are reports suggesting that there are as many as 80
molecular markers in the skin compartment that show good correlation
with venous blood [20]. A recent study in animals has shown a good cor-
relation between the concentration and dynamics of many drugs in ISF
and venous blood . Therapeutic drug monitoring in the interstitial[11]
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ﬂuid u sing min imally in vasive devices fo r contin uous or perio d ical
monitoring of drugs with narrow therapeutic index offers a potential
route to per sonalisation of medication regimes.
Despite the promise of minimally invasive continuous monitoring,
experience with CGM using some of the approved commercial devices
such as those from Medtronic (Enlite), Dexcom (G5) and Abbott (Free-
Style Libre) has revealed that their uptake is still 10% despite nearlyb
two and half decade s of re search and develo pment [10 ,16]. T h i s c a n
be attri buted main ly to poor ac curacy an d precisio n (givin g rise to
many fa lse ala rms) an d high costs of dev ice man ufactu re. Curre nt
CGM devices are mostly subcutaneously implanted and hence the em-
phasis has been on long term performance. Our approach has been to
use a minimally invasive microneedle array format where the sensors
can be readily and painlessly inserted and where the cost is sufﬁciently
low that daily replac ement is feasibl e. Th is c ould give all the proven
beneﬁts of continuous monitoring at a price comparable to the current
single measurement strips. We report here on methods used for fabrica-
tion of such microneedle arrays.
To achieve the low cost and scalable manufacture injection molding
of polycarbonate yielded 300-microneedle structures/hour. Mechanical
characterisation of these structures is presented and their functionalisa-
tion to pr oduce gluc ose, la ctate and t heophyl line biosens ors is de -
scribed. The characterisation of these, as well as studiesin vitro in vivo
on human sk in illu strates th eir performance.
2. Experimental section
2.1. Materials
Cu\\W, aluminum blocks and hardened stainless steel stamps were
obtain ed from Erod ex, UK respe ctively . Phen ol was obtain ed from
Sigma-Aldrich, UK. Glucose oxidase (Glucose Oxidase HPS300, Sekisui
Diagnostics (U.K.), Ltd., Units, Activity 239 U/mg powder @ 25 °C, source
ExAspergillus niger) and lactate oxidase (Lactate Oxidase II, Sekisui Diag-
nostics (U.K.), Ltd., Units, Activity 41 U/mg powder @ 37 °C, source Ex
Aerococcusvinidans) were employed as the enzymes for glucose and lac-
tate sensors respectively. Xanthine oxidase (Xanthine Oxidase microbi-
al, Sigma Aldrich U.K., N7 U /mg powder) was used for th e theophylline
sensor.
2.2. Fabrication of the base microneedle array
Copper tungsten and stainless steel masters, fabricated using elec-–
tric discharge milli ng ( EDM ), wer e the n us ed as electr odes fo r sp ark
erosion of aluminum blocks to create molds. The spark erosion was re-
peated up to six times. In one instance, the molds were washed with a
pressurized jet to remove the eroded debris. In another example, the
aluminum mold created by EDM was pressed against a hardened stain-
less steel master. For the injection molding, a hydraulic injection-mold-
ing machine (Victory 28, Engel) was used to manufacture the samples.
The molde d pa rts were man ufactu red in p olycarb onate (Mak rolon
OD201 5) which was drie d at 110 °C for 24 h unde r vacuum prio r to
use. The EDM prepared aluminum master inlay was inserted into the
tool which was desig ned to produce parts measu ring
≈25 × 25 × 2 mm or 25 × 25 × 1 mm. For the manufac turing of the
part, we applied the following conditions to the injection molding pro-
cess: Tm = 270 °C (PC melt temperature), Tw = 80 °C (tool tempera-
ture), vi = 20 cm 3 s−1(injection speed), shot volume of 4.4 cm 3 and a
cooling time (tc ) of 5 s. This resulted in a total cycle time 12 s for each
sample.
2.3. SEM characterisation
The bare devices were sputtered with 50 nm chromium and imaged
using a JEOL 5610 scanning electron microscope.
2.4. Mechanical evaluation
2.4.1. Measurement of axial compression force
The effect of applying an axial compression load to the microneedle
array was assessed using an Instron 5866 instrument with a 500 N load






























































Fig. 1. Dose-response curves obtained for glucose, lactate and theophylline. Panel (a) is a
dose - respo nse curve ob taine d fr o m th ree worki ng elec trodes fu nction alise d wi th
glucose oxidase entrapped in polyphenol but without an epoxy PU membrane. In panels
(b) and (c) the red curves are for working electrodes coated with epoxy PU membrane
and the black curves are for working electrodes without the membrane.
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cell. Micron eedle arrays were pla ced on a xed metal plate wit h th eﬁ
microneedles facing upwards before applying the desired force through
the movable probe of the Instron compression system. The Instron in-
strumen t appli ed pressu re on the m ic roneed le array s using an axia l
force (parallel to the microneedles' axes) at a rate of 1 mm/s until the re-
quired force was exerted. Forces ranging from 50 N to 400 N were test-
ed. Scanning electron microscopy of microneedle arrays was obtained
befor e and after applic ation of the compr es sion load. The hei ght of
each micro n eedle was measure d afte r test ing and t he per centage
change in microneedle height calculated.
2.4.2. Measurement of transverse fracture force
The transverse failure forces of microneedle arrays were measured
with the same force station as described above. A thin probe (Agar Sci-
entiﬁc) (2 mm thickness at the tip) was slotted in the clamp and used
for this purpose. It was adjusted to ensure that it pressed orthogonally
against a row of eight microneedles. The probe was moved at a speed
of 1 mm/min. The force required to fracture a single microneedle was
determined by divi ding the transverse force required to fracture one
row by the number of mic roneed les in each row (fou r). The
microneedle arrays were examined by scanning electr on microscopy
prior to and after fracture testing.
2.5. Functionalisation
Bare microneedle arrays were sputtered with chromium (15 nm)/
Platin um (50 nm) to obta in the workin g elect rodes. One of the
microneedle arrays was sputtered with Ag (150 nm), which was modi-
ﬁed to an Ag/AgCl reference electrode by treating with a saturated solu-
tion of FeCl3 . The working electrodes were biased against the integrated
Ag/AgCl reference electrodes for electropolymerisation and subsequent
chronoamperometry measurements.
The gluc ose, lac tate and th eophyllin e biose nsors des cribed h ere
were fabric ated using an electrop olymeri sation method . For
electropoly merised polyphenols, the electrode was placed in 50 mM
phenol monomer and 10 mg/mL of GOx/LOx/XOx enzyme dissolved in
100 mM PB S. Th e pH of the solu tion wa s bu ffered to pH 7.2. Each
cycle com prised of holdi ng the work ing el ectrod e at 0 V for 20 s ,
polarising it to a potential of 0.9 V for 15 min for electropolymerisation
of th e ﬁlm. Each cycle was repeated six times to obtain the desired ﬁlm
thickness and enzyme loading.
Using 200 L of various concentrations of glucose, lactate and the-
ophylline solutions, chronoampero metric mea surements were made
over 60 s. From these measurements, dose response curves were ob-
tained fo r gluc ose, lactate a nd t heophylline biose nsors.
2.6. Optical coherence tomography of microneedles in human tissue
Unfunc tionalis ed de vices were steri lized by s ubjectin g them to
25 kGy of Co 60 (Sy nergy Healt h) b efore the inser tion studi es. Th e
microneedle array structures were inserted into the forearm of volun-
teers by the application of moderate thumb pressure ( 10 N) for 60 s.b
Optical coherence tomography (details) based has been reportedly
used by several groups to look at the skin penetration . On removal[5]
of the device, OCT equipment (Vivosight, Michelson diagnostics) was
used to look at the pen etration of th e stra tum corneum.
3. Results
3.1. SEM characterisation
The SEM images were analysed for geometry. Each injection molded
part was 20 × 20 mm with a 2 mm thick base and comprising 4 arrays
each of which had 16 microneedles in a 4 × 4 subarray. The individual
microneed les were pyra midal in sh ape; 1000 m tall, with a 600 m
square base an d a ti p d iameter of ~ 40 m . Th e p itch bet ween the
microneedles is 1200 m.
3.2. Mechanical evaluation
In axial compres sion tests (n = 4) the microneedles tolerated large
forces without fracture. The reduction of microneedle height increased
non-li nearly with incre asing appli ed force. This ranged from 1% for
50 N to 17% fo r 400 N a xial force s. Tr ansver se fractur e te sts (n = 3 )
showed that the force required to fracture one row of four microneedles
was 80 ± 3 N (20 N per microneedle).
3.3. Functional evaluation
The functionalised devices were tested with varying glucose, lactate
and theophylline concentrations using chronoamperometry. From the
chronoamperome try studies the do se respon se cur ves were tt ed toﬁ
the Michaelis-Menten equation ( ).Fig. 1
As seen from the dose response curves, glucose and lactate concen-
tration as low as 0.5 mM could be easily detected. For the glucose bio-
sensors, the three microneedle electrode arrays within a single device
exhibit ed Km valu es of 11.4 ± 2.7 mM, 13. 9 ± 5.9 mM and 15 .5 ±
9.6 mM. The corresponding I max values for the three elect rodes were
20 .3 ± 2.4 A a nd 2 5.5 ± 8. 7A, 23.6 ± 5.4 A (Ta ble 1).
The I max values were found to be low for the lactate and theophylline
biosenso rs. Th is can be attrib uted to the low activit y of the enzymes
used her e (Lact ate oxid ase 41 U/ mg powd er and X an thine ox idase
7 U/mg powder @ 37 °C). With the lactate biosensors, the microneedle
array el ectrod es exhib ited K m va lues of 3.03 ± 0.9 mM wi th the
epoxy polyurethane (PU) membrane and 0.7 ± 0.08 mM respectively.
The I max values for the two electro des wer e 2. 5 ± 0.2 A and 0.95 ±
0.06 A respectively. Similarly, the theophylline biosensors exhibited
Km values of 31 ± 1.22 M with the epoxy polyurethane (PU) mem-
brane and 13 ± 1.84 M respectively. The Imax valu es f or the two ele c-
trodes were 0.52 ± 0.05 A and 0.31 ± 0.008 A respectively.
Table 1
Showing the Michaelis-Menten KM constant and the maximum limiting current Imax for the three biosensors.
Biosensor Enzyme Km Imax
Theophylline biosensor Xanthine oxidase (7 U/mg)
With epoxy PU membrane 31 M ± 1.22 0.52 A ± 0.05
Without membrane 13 M ± 1.84 0.31 A ± 0.008
Lactate biosensor Lactate oxidase (41 U/mg)
With epoxy PU membrane 3.03 mM ± 0.9 2.5 A ± 0.2
Without membrane 0.7 mM ± 0.08 0.95 A ± 0.06
Glucose biosensor Glucose oxidase (239 U/mg)
WE1 no membrane 11.4 mM ± 2.74 20.3 A ± 2.45
WE2 no membrane 13.9 mM ± 5.9 23.6 A ± 5.4
WE3 no membrane 15.5 mM ± 9.6 25.5 A ± 8.71
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Whilst the increase in linear range is expected for a mass transport
limiting membrane, it would also be expected to reduce the maximum
current. A possible explanation for the increased limiting currents is that
the membrane reduces the rate of diffusion of hydrogen peroxide away
from the electrode surface, resulting in an increased local concentration
quickly consequently leading to a higher current.
3.4. Insertion test on human skin
The inser tion ratio, as determined from the tests ( = 16)n in vivo
(human skin) was 100% for very moderate forces ( 10 N). Whilst theb
SEM of the microneedle arrays following insertion tests con rmed theﬁ
structural integrity of the device the OCT images con rm the penetra-ﬁ
tion of the stratum corneum ( ).Fig. 2
It is observ ed that t he channels c reated by pe netrat ion of
micro n eedles collapse on account of the high ly elast ic nature of the
skin layers t herefore OCT was d one with device inserted.
4. Conclusions
Next generati on wearable devices will carry minima lly in vasiv e,
continuous monitoring systems for metabolites, biomarkers and drugs
and will have implications for the better management of both lifestyle
and chro nic dis ea ses. We ha ve demons trated h ere a scala ble (300/
hour) and cost effective approach to fabricating polycarbonate-based
(material cost of 2 pence) microneedle structures with desired geome-
try and mechanical properties. The sterilized structures were tested on
human skin and it was observed that the geometry of the tips allowed
penetra tion of the stratum corneum and access to the dermal interstitial
ﬂuid by in sertion under modera te thu mb pr essure. The microneed le
arrays could subsequently be functionalised to perform as electrochem-
ical biosen sors.
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